In vitro and in vivo imaging of peptide-encapsulated polymer nanoparticles for cancer biomarker activated drug delivery

IEEE Transactions on Nanobioscience

Volumn 12, Issue 4, 2013, Pages 304-310

  Kulsharova, Gulsim K ^a   Lee, Matthew B ^a   Cheng, Felice ^a   Haque, Munima ^a   Choi, Hyungsoo ^a   Kim, Kyekyoon ^b   O'Brien, William D ^b   Liu, G Logan ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b University of Illinois at Urbana Champaign   (United States)

Author keywords

Chemotherapy; Doxorubicin; Gelatin nanoparticles; In vivo ultrasound imaging; Targeted drug delivery

Indexed keywords

BREAST CANCER TREATMENT; COATED NANOPARTICLES; DOXORUBICIN; GELATIN NANOPARTICLES; MAMMARY CARCINOMA CELL; POLYMER NANOPARTICLES; TARGETED DRUG DELIVERY; ULTRASOUND IMAGING;

CELL CULTURE; CELLS; CHEMOTHERAPY; DISEASES; DRUG DELIVERY; EXPERIMENTS; MAMMALS; PEPTIDES; ULTRASONIC IMAGING;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG CARRIER; NANOPARTICLE; POLYMER; TUMOR MARKER;

ANIMAL; ARTICLE; BREAST TUMOR; CHEMISTRY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; MCF 7 CELL LINE; METABOLISM; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; MCF-7 CELLS; MICE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; POLYMERS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892599258     PISSN: 15361241     EISSN: None     Source Type: Journal    
DOI: 10.1109/TNB.2013.2274781     Document Type: Article

References (19)

1. H. T. Ta, C. R. Dass, I. Larson, P. F. M. Choong, and D. E. Dunstan. "A chitosan-dipotassium orthophosphate hydrogel for the delivery of doxorubicin in the treatment of osteosarcoma. " Biomaterials, vol. 30, no. 21, pp. 3605-3613, Jul. 2009.
2. L. J. Wood, L. M. Nail, A. Gilster, K. A. Winters, and C. R. Elsea. "Cancer chemotherapy-related symptoms: Evidence to suggest a role for proinflammatory cytokines. " Oncol. Nurs. Forum, vol. 33, no. 3, pp. 535-542, May 2006. (Pubitemid 44870222)
3. O. Tacar, P. Sriamornsak, and C. R. Dass. "Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. " J. Pharmacy Pharmacol., vol. 10, Aug. 2012.
4. R. Herrero-Vanrell, A. C. Rincón, M. Alonso, V. Reboto, I. T. Molina-Martinez, and J. C. Rodríguez-Cabello. "Self-Assembled particles of an elastin-like polymer as vehicles for controlled drug release. " J. Control. Rel., vol. 102, no. 1, pp. 113-122, Jan. 2005. (Pubitemid 40093779)
5. C. Vauthier, C. Dubernet, C. Chauvierre, I. Bigger, and P. Couvreur. "Drug delivery to resistant tumors: The potential of poly (alkyl cyanoacrylate) nanoparticles. " J. Control. Rel., vol. 93, no. 2, pp. 151-160, Dec. 2003. (Pubitemid 37421357)
6. G. G. Pitt, M. M. Gratzel, G. L. Kimmel, J. Surles, and A. Sohindler. "Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (å-caprolactone), and their copolymers in vivo. " Biomaterials, vol. 2, no. 4, pp. 215-220, Oct. 1981. (Pubitemid 12195194)
7. M. Barratt. "Therapeutic applications of colloidal drug carriers. " Pharmaceut. Sci. Tech. Today, vol. 3, no. 5, pp. 163-171, May 2000.
8. P. Couvreur, C. Dubernet, and F. Pusieux. "Controlled drug delivery with nanoparticles: Current possibilities and future trends. " Eur. J. Pharm. Biopharm., vol. 41, no. 1, pp. 2-13, 1995.
9. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori. "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. " J. Control. Rel., vol. 65, no. 1-2, pp. 271-284, 2000. (Pubitemid 30122932)
10. H. Maeda. "The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selectivemacromolecular drug targeting. " Adv. Enzyme Regul., vol. 41, no. 41, pp. 189-207, 2001.
11. A. K. Iyer, G. Khaled, J. Fang, and H. Maeda. "Exploiting the enhanced permeability and retention effect for tumor targeting. " Drug Discov. Today, vol. 11, no. 17-18, pp. 812-818, Sep. 2006. (Pubitemid 44280021)
12. N. Ferrara, K. J. Hillan, H. P. Gerber, and W. Novotny. "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. " Nat. Rev. Drug Discov., vol. 3, pp. 391-400, May 2004. (Pubitemid 38618122)
13. M. Arruebo, M. Valladares, and A. Gonzalez-Fernandez. "Antibodyconjugated nanoparticles for biomedical applications. " J. Nanomater., vol. 2009, pp. 24-24, Sep. 2009.
14. P. A. Trail, D. H. King, and G. A. Dubowchik. "Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. " Cancer Immunol. Immunother., vol. 52, no. 5, pp. 328-337, Jan. 2003. (Pubitemid 36578026)
15. M. E. Akerman, W. C. W. Chan, P. Laakkonen, S. N. Bhatia, and E. Ruoslahti. "Nanocrystal targeting in vivo. " Proc. Natl. Acad. Sci. USA, vol. 99, p. 12617, 2002.
16. N. D. Rawlings, F. R. Morton, and A. J. Barrett. "MEROPS: The peptidase database. " Nucleic Acids Res., vol. 27, no. 1, pp. 325-331, Jan. 1999. (Pubitemid 29209475)
17. Y. B. Choy, F. Cheng, H. C. Choi, and K. Kim. "Monodisperse gelatin microspheres as a drug delivery vehicle: Release profile and effect of crosslinking density. " Macromol. Biosci., vol. 8, no. 8, pp. 758-765, Aug. 2008.
18. Y. B. Choy, H. Choi, and K. Kim. "Uniform biodegradable hydrogel microspheres fabricated by a surfactant-free electric-field-Assisted method. " Macromol. Biosci., vol. 7, no. 4, pp. 423-428, Apr. 2007. (Pubitemid 47237517)
19. G. Hermanson. "EDC plus sulfo-NHS. " in Bioconjugate Techniques, 2nd ed. New York: Academic, 2008, pp. 216-220.